Amoytop Biotech
China - XiamenBiotechnology
Focus: Amoytop Biotech is a China-based public biologics company focused on biosimilars and recombinant proteins across infectious diseases, women's health, hematology, oncology, and immunology. The company operates from Xiamen with an active pipeline of 13 programs across multiple therapeutic areas.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Amoytop Biotech
AI assessmentNot HiringNo open roles listed right now. Follow Amoytop Biotech to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthStrong
Pipeline
Late-stage
4 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
PegIFN α- 2b
Chronic Hepatitis BClinical Trials (1)
NCT05451420Inactive HBsAg Carriers (IHCs) Treated With Pegylated Interferon α2b Based Intervention Therapy
N/AHelp build intelligence for Amoytop Biotech
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.